NEW YORK, NY / ACCESSWIRE / June 6, 2018 / Major indexes closed mostly higher Tuesday, lifted by a rally from the technology sector. The Dow Jones Industrial Average decreased 0.06 percent to close at 24,799.98, weighed by losses from consumer-staples and financial sectors, while the S&P 500 Index climbed 0.07 percent to close at 2,748.80. The Nasdaq Composite Index was up 0.41 percent to close at 7,637.86.
“Our view is that the current economic expansion and bull market has room to run and we aren’t looking at the prospect of a recession starting until 2020 at the earliest,” said Albert Brenner, director of asset allocation strategy at People’s United Advisors.
RDI Initiates Coverage on:
Aurora Cannabis Inc.
Aurora Cannabis’ stock jumped 6.18% Tuesday, to close the day at $6.70. The stock recorded a trading volume of 2,228,625 shares, which was above its three months average volume of 1,541,490 shares. In the last year, Aurora Cannabis’ shares have traded in a range of 1.40 – 12.30. The share price has gained 378.57% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $6.30 is below its 200-day moving average of $7.44. Shares of the company are trading at a Price to Earnings ratio of 478.57. Shares of Aurora Cannabis have gained roughly 7.06 percent in the past month and are down 12.19 percent year-to-date.
Access RDI’s Aurora Cannabis Inc. Research Report at:
On Tuesday, shares of MedReleaf recorded a trading volume of 128,525 shares, which was below the three months average volume of 158,638 shares. The stock ended the day 5.21% higher at $20.25. The share price has fallen 18.97% from its 52-week high with a 52-week trading range of 5.86 – 24.99. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $17.82 is above its 200-day moving average of $15.79. Shares of MedReleaf have gained roughly 11.71 percent in the past month and are up 20.57 percent year-to-date.
Access RDI’s MedReleaf Corp. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer .
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.